SUCCESSFUL TREATMENT OF LUPUS NEPHRITIS IN MRL-LPR LPR MICE BY INHIBITING ORNITHINE DECARBOXYLASE

被引:20
|
作者
GUNNIA, UB
AMENTA, PS
SEIBOLD, JR
THOMAS, TJ
机构
[1] UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, CLIN RES CTR, NEW BRUNSWICK, NJ 08903 USA
[2] UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT MED, DIV RHEUMATOL, NEW BRUNSWICK, NJ 08903 USA
[3] UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT PATHOL, NEW BRUNSWICK, NJ 08903 USA
关键词
D O I
10.1038/ki.1991.111
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Ornithine decarboxylase (ODC) is a key enzyme in the biosynthesis of cellular polyamines, putrescine, spermidine and spermine. Difluoromethylornithine (DFMO) is an irreversible inhibitor of ODC and thereby depletes putrescine and spermidine levels in vivo and in vitro. Previous studies in lupus-prone MRL-lpr/lpr mice treated with 1% DFMO in drinking water have been associated with improved lifespan, and reduced anti-DNA antibody production, lymphadenopathy, and splenic polyamine levels. Since glomerulonephritis is a major cause of morbidity and mortality in lupus, we studied the effect of DFMO on renal histology of MRL-lpr/lpr mice. Female BALB/c and MRL-+/+ mice were used as controls. Dose response studies revealed that 1.5% DFMO in drinking water had maximum therapeutic efficacy and produced a significant 79% increase in the median lifespan of a group of 20 mice compared to an equal number of controls (P < 0.001). Renal histologic studies were performed on kidney sections from four to five mice each from DFMO-treated and untreated groups at 12, 16, 20, 24 and 29 weeks of age. Sections were read blinded to duration and treatment and scored by four major histologic criteria (glomerulonephritis, interstitial inflammation, perivascular inflammation, and vasculitis) and showed significant reduction in all these parameters in DFMO-treated mice when compared to age- and sex-matched untreated mice of the same strain. DFMO treatment had no significant effect on pulmonary histologic findings on these mice. DFMO treatment reduced ODC activity and polyamine concentrations in treated mice. Basal ODC activity of 24-week-old untreated and DFMO-treated MRL-lpr/lpr mice was 142 +/- 14 and 27 +/- 6 pmol CO2/mg protein/hr, respectively. Basal kidney ODC activity of normal BALB/c and MRL-+/+ mice was 78 +/- 14 and 93 +/- 21 pmol CO2/mg protein/hr, respectively and indicated a constitutively high level of ODC activity in lupus-prone MRL-lpr/lpr mice compared to other strains. These data suggest an important role of endogenous polyamines in the tissue injury of lupus and suggest novel approaches to therapy of lupus-related renal disease.
引用
收藏
页码:882 / 890
页数:9
相关论文
共 50 条
  • [21] Treatment of Lupus-prone MRL-lpr Mice with the Mitochondrial Antioxidant MitoQ
    Budd, Ralph
    Fortner, Karen
    Blanco, Luz
    Kaplan, Mariana
    Perl, Andras
    Busliewicz, Iwona
    MacPherson, Greg
    Murphy, Mike
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [22] FURTHER SEROLOGICAL AND RFLP ANALYSIS OF THE MRL-+ + AND MRL-LPR LPR MICE
    DELARBRE, C
    BOBE, P
    KIGER, N
    KOURILSKY, P
    GACHELIN, G
    JOURNAL OF IMMUNOGENETICS, 1988, 15 (5-6): : 307 - 319
  • [23] EFFECT OF MACROPHAGE ACTIVATION ON LUPUS NEPHRITIS IN MRL/MPJ-LPR/LPR(MRL/L)MICE
    IZUMINO, K
    FUTAMURA, A
    NAKAGAWA, Y
    ENTANI, C
    TAKATA, M
    INOUE, H
    IIDA, H
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1995, 6 (03): : 870 - 870
  • [24] ALLOPHENIC CHIMERAS OF AUTOIMMUNE MRL-LPR LPR AND NORMAL MICE
    NENAZEE, D
    BURKI, K
    EXPERIENTIA, 1987, 43 (06): : 630 - 630
  • [25] Expression of Natural Autoantibodies in MRL-lpr Mice Protects from Lupus Nephritis and Improves Survival
    Mannoor, Kaiissar
    Matejuk, Agata
    Xu, Yang
    Beardall, Michael
    Chen, Ching
    JOURNAL OF IMMUNOLOGY, 2012, 188 (08): : 3628 - 3638
  • [26] Topical Endocannabinoid Administration Protects MRL-Lpr/Lpr Mice from Cutaneous Lupus Erythematosus
    Chalmers, Samantha
    Garcia, Sayra
    Draganski, Andrew
    Doerner, Jessica
    Friedman, Adam
    Friedman, Joel
    Putterman, Chaim
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [27] TREATMENT WITH HUMAN LEUKOCYTE ANTIGEN (HLA-G) ATTENUATES PROGRESSION OF LUPUS NEPHRITIS IN MRL-lpr MICE
    Kulkarni, Onkar
    Mulay, Shrikant
    Darisipudi, Murthy
    Kumar, Santhosh
    LeMaoult, Joel
    Carosella, Edgardo D.
    Anders, Hans-Joachim
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 42 - 42
  • [28] Deficiency of the TWEAK Receptor Fn14 Is Protective In the MRL-Lpr/Lpr Mouse Model of Lupus Nephritis
    Xia, Yumin
    Wen, Jing
    Michaelson, Jennifer S.
    Burkly, Linda C.
    Putterman, Chaim
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S212 - S213
  • [29] ALW peptide ameliorates lupus nephritis in MRL/lpr mice
    Huixia Wang
    Mei Lu
    Siyue Zhai
    Kunyi Wu
    Lingling Peng
    Jie Yang
    Yumin Xia
    Arthritis Research & Therapy, 21
  • [30] REGULATION OF PATHOGENIC ANTINEUTROPHIL CYTOPLASM ANTIBODY IN MRL-LPR/LPR MICE
    HARPER, JM
    MILSTEIN, C
    COOKE, A
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1995, : 143 - 143